No connection

Search Results

BDX vs COR

BDX
Becton, Dickinson and Company
NEUTRAL
Price
$156.41
Market Cap
$56.67B
Sector
Healthcare
AI Confidence
90%
COR
Cencora, Inc.
NEUTRAL
Price
$361.94
Market Cap
$70.85B
Sector
Healthcare
AI Confidence
65%

Valuation

P/E Ratio
BDX
25.56
COR
45.47
Forward P/E
BDX
11.57
COR
22.12
P/B Ratio
BDX
1.76
COR
40.17
P/S Ratio
BDX
2.58
COR
0.22
EV/EBITDA
BDX
10.52
COR
15.32

Profitability

Gross Margin
BDX
46.78%
COR
3.51%
Operating Margin
BDX
13.35%
COR
1.14%
Profit Margin
BDX
8.01%
COR
0.48%
ROE
BDX
6.96%
COR
123.75%
ROA
BDX
4.08%
COR
3.26%

Growth

Revenue Growth
BDX
1.6%
COR
5.9%
Earnings Growth
BDX
28.6%
COR
--

Financial Health

Debt/Equity
BDX
0.77
COR
4.38
Current Ratio
BDX
1.05
COR
0.9
Quick Ratio
BDX
0.37
COR
0.51

Dividends

Dividend Yield
BDX
2.67%
COR
0.66%
Payout Ratio
BDX
68.14%
COR
27.64%

AI Verdict

BDX NEUTRAL

BDX shows neutral fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Mixed signals with both opportunities and risks present.

Strengths
Company has established market presence
Risks
Limited historical data available for full assessment
COR NEUTRAL

Cencora (COR) trades at a premium valuation with strong 5-year price performance (+271.1%) and solid earnings growth (YoY EPS +15.0%), supported by consistent quarterly beats (22 of 25 quarters) and improving margins. However, its profitability metrics remain weak relative to peers—particularly gross margin (3.51%) and operating margin (1.14%)—while elevated leverage (Debt/Equity 4.38) and deteriorating liquidity (Current Ratio 0.90) raise structural concerns. The stock is priced for perfection with a P/E of 45.47, well above the sector average of 36.87, despite lower-than-peer revenue growth (5.9% vs 10.5%). Notably, recent insider selling totaling $18.51M over the past six months contrasts with a bullish analyst consensus, creating a mixed signal that tempers enthusiasm.

Strengths
Consistent earnings outperformance: 22 of 25 quarters beat estimates, with an average surprise of 4.53% over the last four quarters
Strong long-term price momentum: +271.1% return over 5 years, significantly outperforming most healthcare peers
High ROE of 123.75% suggests efficient use of equity capital, likely amplified by high financial leverage
Risks
Extremely high leverage with Debt/Equity of 4.38, more than triple the sector average of 1.18, increasing refinancing and interest rate risk
Deteriorating liquidity: Current Ratio of 0.90 and Quick Ratio of 0.51 indicate potential near-term solvency pressure
Very low profitability: Gross margin of 3.51% and operating margin of 1.14% are far below sector averages of 14.05% and ~20%, respectively

Compare Another Pair

BDX vs COR: Head-to-Head Comparison

This page compares Becton, Dickinson and Company (BDX) and Cencora, Inc. (COR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile